Saroja Pharma Industries India Ltd
Incorporated in 2023, Saroja Pharma Ltd is mainly in the business of trading Thionyl Chloride chemical and pharmaceutical intermeddles, etc.[1]
- Market Cap ₹ 17.6 Cr.
- Current Price ₹ 43.7
- High / Low ₹ 62.0 / 34.0
- Stock P/E 17.1
- Book Value ₹ 39.0
- Dividend Yield 0.00 %
- ROCE 12.6 %
- ROE 6.79 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.12 times its book value
- Company's working capital requirements have reduced from 39.6 days to 29.8 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.0% over last 3 years.
- Company has high debtors of 180 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
36.66 | 55.63 | 50.19 | 40.67 | 53.92 | |
35.36 | 53.53 | 47.47 | 38.11 | 50.95 | |
Operating Profit | 1.30 | 2.10 | 2.72 | 2.56 | 2.97 |
OPM % | 3.55% | 3.77% | 5.42% | 6.29% | 5.51% |
0.09 | 0.32 | 0.16 | 0.19 | 0.00 | |
Interest | 0.33 | 0.80 | 1.32 | 1.45 | 1.41 |
Depreciation | 0.02 | 0.05 | 0.07 | 0.09 | 0.11 |
Profit before tax | 1.04 | 1.57 | 1.49 | 1.21 | 1.45 |
Tax % | 28.85% | 28.03% | 28.86% | 27.27% | 28.97% |
0.73 | 1.14 | 1.06 | 0.88 | 1.03 | |
EPS in Rs | 730.00 | 50.49 | 3.61 | 2.19 | 2.56 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -1% |
TTM: | 33% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -3% |
TTM: | 17% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -25% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 10% |
Last Year: | 7% |
Balance Sheet
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 0.01 | 0.23 | 2.94 | 4.02 | 4.02 |
Reserves | 0.93 | 3.80 | 2.15 | 10.62 | 11.66 |
3.02 | 6.14 | 10.18 | 5.73 | 9.46 | |
4.26 | 5.34 | 6.07 | 6.20 | 14.41 | |
Total Liabilities | 8.22 | 15.51 | 21.34 | 26.57 | 39.55 |
0.09 | 0.34 | 2.22 | 2.51 | 2.51 | |
CWIP | 0.00 | 0.00 | 1.79 | 6.13 | 8.61 |
Investments | 0.00 | 0.04 | 0.14 | 0.20 | 0.34 |
8.13 | 15.13 | 17.19 | 17.73 | 28.09 | |
Total Assets | 8.22 | 15.51 | 21.34 | 26.57 | 39.55 |
Cash Flows
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
-1.05 | -3.67 | 2.19 | 1.02 | 1.15 | |
-0.05 | -0.34 | -4.82 | -4.76 | -2.70 | |
1.03 | 4.27 | 2.73 | 3.70 | 1.56 | |
Net Cash Flow | -0.07 | 0.26 | 0.10 | -0.04 | 0.01 |
Ratios
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 71.88 | 91.73 | 80.80 | 145.75 | 179.93 |
Inventory Days | 7.23 | 3.41 | 31.18 | 4.10 | 0.75 |
Days Payable | 45.43 | 38.52 | 47.22 | 57.45 | 102.56 |
Cash Conversion Cycle | 33.68 | 56.62 | 64.76 | 92.39 | 78.12 |
Working Capital Days | 22.20 | 33.07 | 17.16 | 71.71 | 29.78 |
ROCE % | 33.55% | 22.09% | 14.93% | 12.57% |
Documents
Announcements
-
Trading Window
27 September 2025 - Trading window closed 01-Oct-2025 until 48 hours after unaudited H1 results for 30-Sep-2025.
-
Cessation
26 September 2025 - CFO Manish Dasharath Kamble resigned effective close of business September 25, 2025.
-
Cessation
24 September 2025 - Whole-time Director Manish Dasharath Kamble resigned effective close of business September 23, 2025.
-
Copy of Newspaper Publication
8 September 2025 - Saaroja Pharma: 07th AGM on 30 Sep 2025; newspaper notice published; e-voting details; cut-off date 23 Sep 2025.
-
Copy of Newspaper Publication
8 September 2025 - Saaroja Pharma: 07th AGM on 30 Sep 2025; e-voting details; cut-off date 23 Sep 2025.
Business Overview:[1]
SPIIL is in the business of trading in Pharma API, Pharma Intermediates, Chemicals, Solvents, and other pharmaceutical products, used
for human and veterinary medicine